Zolinza is a brand name of vorinostat, approved by the FDA in the following formulation(s):
ZOLINZA (vorinostat - capsule; oral)
Manufacturer: MERCK
Approval date: October 6, 2006
Strength(s): 100MG [RLD]
Has a generic version of Zolinza been approved?
No. There is currently no therapeutically equivalent version of Zolinza available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zolinza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Potent inducers of terminal differentiation and methods of use thereof
Patent 6,087,367
Issued: July 11, 2000
Inventor(s): Breslow; Ronald & Marks; Paul A. & Rifkind; Richard A. & Jursic; Branko
Assignee(s): Sloan-Kettering Institute for Cancer Research
The Trustees of Columbia University in the City of New York
The present invention provides the compound having the structure: ##STR1## wherein each of R.sub.1 and R.sub.2 are independently the same as or different from each other; when R.sub.1 and R.sub.2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; when R.sub.1 and R.sub.2 are different, R.sub.1 =R.sub.3 --N--R.sub.4, wherein each of R.sub.3 and R.sub.4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R.sub.3 and R.sub.4 bond together to form a piperidine group and R.sub.2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8. The present invention also provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.
Patent expiration dates:
Methods of treating cancer with HDAC inhibitors
Patent 7,399,787
Issued: July 15, 2008
Inventor(s): Chiao; Judy H. & Bacopoulos; Nicholas G. & Miller; Thomas A. & Paradise; Carolyn M. & Richon; Victoria M.
Assignee(s): Merck HDAC Research, LLC
The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
Patent expiration dates:
Polymorphs of suberoylanilide hydroxamic acid
Patent 7,456,219
Issued: November 25, 2008
Inventor(s): Miller; Thomas A. & Richon; Victoria M. & Chiao; Judy H.
Assignee(s): Merck HDAC Research, LLC
The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.
Patent expiration dates:
- November 14, 2026
✓
Drug substance
Polymorphs of suberoylanilide hydroxamic acid
Patent 7,652,069
Issued: January 26, 2010
Inventor(s): Miller; Thomas A. & Richon; Victoria M.
Assignee(s): Merck HDAC Research, LLC
The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.
Patent expiration dates:
- March 4, 2023
✓
Drug product
Methods of treating cancer
Patent 7,732,490
Issued: June 8, 2010
Inventor(s): Richon; Victoria M. & Chiao; Judy H. & Kelly; William Kevin & Miller; Thomas A.
Assignee(s): Merck HDAC Research, LLC
Sloan-Kettering Institute for Cancer Research
The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
Patent expiration dates:
Polymorphs of suberoylanilide hydroxamic acid
Patent 7,851,509
Issued: December 14, 2010
Inventor(s): Miller; Thomas A. & Richon; Victoria M.
Assignee(s): Merck HDAC Research, LLC
The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.
Patent expiration dates:
Methods of treating Hodgkin's and non-Hodgkin's lymphoma
Patent 8,067,472
Issued: November 29, 2011
Inventor(s): Richon; Victoria M. & Chiao; Judy H. & Kelly; William Kevin & Miller; Thomas A.
Assignee(s): Merck HDAC Research, LLC
Sloan-Kettering Institute for Cancer Research
The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
Patent expiration dates:
Formulations of suberoylanilide hydroxamic acid and methods for producing the same
Patent 8,093,295
Issued: January 10, 2012
Inventor(s): Wong; Jeannie Chow & Cohen; Benjamin Max & Cote; Aaron S. & Dienemann; Erik A. & Gallagher; Kimberly & Ikeda; Craig & Moser; Justin & Rajniak; Pavol & Reed; Robert A. & Sell; Brian & Starbuck; Cindy & Tung; Hsien-Hsin & Wang; Qingxi & Capodanno; Vincent R.
Assignee(s): Merck Sharp & Dohme Corp.
The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.
Patent expiration dates:
- May 16, 2026
✓
Drug product
Polymorphs of suberoylanilide hydroxamic acid
Patent 8,101,663
Issued: January 24, 2012
Inventor(s): Miller; Thomas A. & Richon; Victoria M.
Assignee(s): Merck HDAC Research, LLC
The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.
Patent expiration dates:
Potent inducers of terminal differentiation and methods of use thereof
Patent RE38506
Issued: April 20, 2004
Inventor(s): Ronald; Breslow & Paul A.; Marks & Richard A.; Rifkind & Branko; Jursic
Assignee(s): Sloan-Kettering Institute for Cancer Research
The Trustees of Columbia University in the City of New York
The present invention provides the compound having the structure: wherein each of R1 and R2 are independently the same as or different from each other; when R1 and R2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiozoleamino group; when R1 and R2 are different, R1=R3—N—R4, wherein each of R3 and R4 are independently the same as or different from each other and are a hydrogen atom, a hydroxyl group, a substituted or unsubstituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R3 and R4 bond together to form a piperidine group and R2 is a hydroxylamino, hydroxyl, amino, alkylamino, dialkylamino or alkyloxy group; and n is an integer from about 4 to about 8. The present invention also provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition and a therapeutically acceptable amount of the compound above.
Patent expiration dates:
- November 29, 2012
✓
Drug substance
✓
Drug product
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
See also...
- Zolinza Consumer Information (Drugs.com)
- Zolinza Consumer Information (Wolters Kluwer)
- Zolinza Consumer Information (Cerner Multum)
- Zolinza Advanced Consumer Information (Micromedex)
- Zolinza AHFS DI Monographs (ASHP)
- Vorinostat Consumer Information (Wolters Kluwer)
- Vorinostat Consumer Information (Cerner Multum)
- Vorinostat Advanced Consumer Information (Micromedex)
- Vorinostat AHFS DI Monographs (ASHP)
